83 related articles for article (PubMed ID: 9799053)
1. The effect of omeprazole pre- and cotreatment on cerivastatin absorption and metabolism in man.
Sachse R; Ochmann K; Rohde G; Mück W
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):517-20. PubMed ID: 9799053
[TBL] [Abstract][Full Text] [Related]
2. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
[TBL] [Abstract][Full Text] [Related]
3. Lack of drug-drug interaction between cerivastatin and nifedipine.
Sachse R; Brendel E; Mück W; Rohde G; Ochmann K; Horstmann R; Kuhlmann J
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):409-13. PubMed ID: 9726692
[TBL] [Abstract][Full Text] [Related]
4. Influence of cholestyramine on the pharmacokinetics of cerivastatin.
Mück W; Ritter W; Frey R; Wetzelsberger N; Lücker PW; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):250-4. PubMed ID: 9208341
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
6. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
[TBL] [Abstract][Full Text] [Related]
7. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Ochmann K; Rohde G; Unger S; Kuhlmann J
Eur J Clin Pharmacol; 1998 Feb; 53(6):469-73. PubMed ID: 9551706
[TBL] [Abstract][Full Text] [Related]
8. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
Periclou AP; Goldwater R; Lee SM; Park DW; Kim DY; Cho KD; Boileau F; Jung WT
Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
[TBL] [Abstract][Full Text] [Related]
9. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients.
Mück W; Mai I; Fritsche L; Ochmann K; Rohde G; Unger S; Johne A; Bauer S; Budde K; Roots I; Neumayer HH; Kuhlmann J
Clin Pharmacol Ther; 1999 Mar; 65(3):251-61. PubMed ID: 10096257
[TBL] [Abstract][Full Text] [Related]
10. Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Backman JT; Kyrklund C; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2002 Dec; 72(6):685-91. PubMed ID: 12496749
[TBL] [Abstract][Full Text] [Related]
11. Interaction of omeprazole with enteric-coated salicylate tablets.
Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
[TBL] [Abstract][Full Text] [Related]
12. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
[TBL] [Abstract][Full Text] [Related]
13. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
Winston A; Back D; Fletcher C; Robinson L; Unsworth J; Tolowinska I; Schutz M; Pozniak AL; Gazzard B; Boffito M
AIDS; 2006 Jun; 20(10):1401-6. PubMed ID: 16791014
[TBL] [Abstract][Full Text] [Related]
14. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
[TBL] [Abstract][Full Text] [Related]
15. Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects.
Palaparthy R; Pradhan RS; Chan J; Rieser M; Chira T; Galitz L; Awni W; Williams LA
Biopharm Drug Dispos; 2007 Mar; 28(2):65-71. PubMed ID: 17173278
[TBL] [Abstract][Full Text] [Related]
16. Investigation into the role of cephalic stimulation of acid secretion on gastric emptying and appetite following a soup meal using the gastric acid inhibitor omeprazole.
Cecil JE; Francis J; Read NW
Appetite; 2004 Feb; 42(1):99-105. PubMed ID: 15036788
[TBL] [Abstract][Full Text] [Related]
17. The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH.
Abe Y; Inamori M; Togawa J; Kikuchi T; Muramatsu K; Chiguchi G; Kawamura H; Kobayashi N; Kirikoshi H; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol; 2004 Jan; 39(1):21-5. PubMed ID: 14767730
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
Tomilo DL; Smith PF; Ogundele AB; Difrancesco R; Berenson CS; Eberhardt E; Bednarczyk E; Morse GD
Pharmacotherapy; 2006 Mar; 26(3):341-6. PubMed ID: 16503713
[TBL] [Abstract][Full Text] [Related]
19. Effect of itraconazole on cerivastatin pharmacokinetics.
Kantola T; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 1999 Jan; 54(11):851-5. PubMed ID: 10027660
[TBL] [Abstract][Full Text] [Related]
20. Influence of omeprazole on pharmacokinetics of domperidone given as free base and maleate salt in healthy Chinese patients.
Zhang YF; Chen XY; Dai XJ; Zhang YN; Liu QZ; Yu HL; Zhong DF
Acta Pharmacol Sin; 2007 Aug; 28(8):1243-6. PubMed ID: 17640489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
